Turn this role into an interview — a resume and cover letter built around what this employer wants.
Orbis Medicines in Copenhagen is growing its data platform and seeks a Scientific Data Engineer to build systems that capture data accurately for biology and chemistry teams. You will work with researchers to design pipelines, implement ETL processes, and ensure data integrity following FAIR principles.
The role is onsite in Copenhagen, collaborating with software engineers and data scientists to enable AI/ML workflows and scalable data infrastructure for drug discovery.
Orbis is growing fast. As our biology and chemistry teams grow, we need our data infrastructure to scale as well. We are looking for a Scientific Data Engineer to build systems and structures that capture data accurately and smoothly so that the science team can focus on the science.
You’ll work closely with biology, chemistry, design and data science teams to understand how they work and what they need from their data, identify areas for improvement and then build solutions using both commercial and custom tools.
This is a chance to join a growing biotech company at a crucial moment as we invest in our lab and data infrastructure, helping build a cutting‑edge data platform, designing workflows and building pipelines. This role would suit someone who loves data and code. Someone with a chemistry or biology background with a computational focus, or a software engineer with experience working in a scientific environment.
You will be working onsite in Copenhagen.
Please contact Talent Acquisition Partner Mia Danielsen (part of DEDENROTH) if you have any questions about the role or the process.
The Orbis’ nGen platform designs macrocycles with oral bioavailability by combining AI technologies with automated synthesis and high-throughput screening of real compounds.
Orbis Medicines has been awarded a 2025 Endpoints 11 title as one of biopharma's most exciting start‑ups. This marks the first time a Nordic biotech has received this honor – highlighting the disruptive potential of Orbis Medicines. With a recent EUR 90 million Series A funding round, led by top‑tier investors such as NEA, Eli Lilly, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion, Orbis Medicines are well‑positioned for significant growth and long‑term success. The confidence of these investors validates the potential to bring groundbreaking therapies to the market.
Orbis Medicines has an established R&D site in Copenhagen that includes a state‑of‑the‑art laboratory and a team of +40 experienced professionals and scientists. We offer the excitement of a start‑up, opportunities for professional growth, and the opportunity to be at the forefront of biotech innovation. Your ideas and contributions will shape the future of medicine. Please visit the website for more details www.orbismedicines.com.